Substance / Medication

Gemcitabine hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Neoplasm of ovary

Neoplasm of breast

Non-small cell lung cancer

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Impact of tert-butyl alcohol on crystallization kinetics of gemcitabine hydrochloride in frozen aqueous solutions.

Munjal Bhushan, Bansal Arvind K · J Pharm Sci · 2015

PMID: 25393155Observational

cRGD grafted siRNA nano-constructs for chemosensitization of gemcitabine hydrochloride in lung cancer treatment.

Khatri Nirav, Rathi Mohan, Baradia Dipesh et al. · Pharm Res · 2015

PMID: 24792823Observational

[A case of interstitial pneumonia induced by gemcitabine hydrochloride for unresectable bile duct cancer].

Miura Tomofumi, Suzuki Nobuaki, Ozeki Yutaka et al. · Gan To Kagaku Ryoho · 2009

PMID: 19838043Case Report

[Fatal liver failure associated with gemcitabine hydrochloride therapy].

Matsuda Masamichi, Watanabe Goro, Mine Shinji et al. · Gan To Kagaku Ryoho · 2008

PMID: 18195549Case Report

[A case of salvage chemotherapy with gemcitabine hydrochloride and nedaplatin for gemcitabine-refractory pancreatic cancer].

Matsuda Masamichi, Watanabe Goro, Hashimoto Masaji · Gan To Kagaku Ryoho · 2008

PMID: 18195544Case Report

[Effective combination chemotherapy with gemcitabine hydrochloride, S-1 and nedaplatin for recurrent pancreatic cancer--a case report].

Tokairin Yutaka, Iida Michio, Yamazaki Shigeru · Gan To Kagaku Ryoho · 2008

PMID: 19106544Case Report

[A case of unresectable advanced pancreatic tail cancer successfully treated with gemcitabine hydrochloride].

Akutsu Yasunori, Endo Masato, Yoshinaga Yushin et al. · Gan To Kagaku Ryoho · 2005

PMID: 15751642Case Report

[A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/uracil].

Ishikawa Toru, Mizuno Ken-ichi, Watanabe Kouji et al. · Gan To Kagaku Ryoho · 2004

PMID: 15508450Case Report

[A case of advanced pancreatic cancer treated with gemcitabine hydrochloride].

Taniguchi Fumihiro, Matsuda Tetsuro, Tsuda Tomohiro et al. · Gan To Kagaku Ryoho · 2003

PMID: 12938271Case Report

[A case of pancreatic tail cancer with peritoneal carcinosis treated with gemcitabine hydrochloride].

Yamada Takayuki, Roppongi Takashi, Maemura Michio et al. · Gan To Kagaku Ryoho · 2002

PMID: 12465399Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Gemcitabine hydrochloride (substance)
SNOMED CT: 412187004
UMLS CUI: C0771488

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.